Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 73,953 shares of the company's stock in a transaction that occurred on Wednesday, April 16th. The shares were purchased at an average cost of $11.16 per share, with a total value of $825,315.48. Following the completion of the purchase, the director now owns 17,773,727 shares in the company, valued at $198,354,793.32. This trade represents a 0.42 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Friday, April 4th, Ecor1 Capital, Llc bought 196,438 shares of Zymeworks stock. The shares were acquired at an average price of $11.17 per share, with a total value of $2,194,212.46.
- On Wednesday, April 2nd, Ecor1 Capital, Llc purchased 74,360 shares of Zymeworks stock. The stock was acquired at an average price of $11.85 per share, for a total transaction of $881,166.00.
- On Monday, March 31st, Ecor1 Capital, Llc acquired 4,397 shares of Zymeworks stock. The shares were acquired at an average price of $11.75 per share, with a total value of $51,664.75.
- On Wednesday, March 26th, Ecor1 Capital, Llc bought 43,848 shares of Zymeworks stock. The stock was acquired at an average price of $12.24 per share, for a total transaction of $536,699.52.
- On Monday, March 24th, Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock. The stock was bought at an average price of $13.08 per share, for a total transaction of $296,772.12.
- On Friday, March 21st, Ecor1 Capital, Llc acquired 31,033 shares of Zymeworks stock. The shares were bought at an average price of $12.78 per share, with a total value of $396,601.74.
- On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The stock was bought at an average price of $12.64 per share, for a total transaction of $736,987.84.
- On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The shares were bought at an average cost of $12.23 per share, with a total value of $688,267.71.
- On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was purchased at an average cost of $12.48 per share, for a total transaction of $5,845,082.88.
- On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The shares were purchased at an average cost of $11.49 per share, with a total value of $3,684,728.10.
Zymeworks Stock Up 2.5 %
NYSE ZYME opened at $11.53 on Friday. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70. The company has a 50 day moving average price of $12.38 and a 200 day moving average price of $13.52. The firm has a market cap of $802.22 million, a PE ratio of -7.69 and a beta of 1.18.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the company. HC Wainwright raised their price target on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Monday, March 10th. Lifesci Capital assumed coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 target price on the stock. Finally, Citigroup boosted their price target on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.00.
Get Our Latest Analysis on ZYME
Institutional Trading of Zymeworks
A number of institutional investors have recently made changes to their positions in ZYME. Barclays PLC raised its stake in Zymeworks by 476.3% in the third quarter. Barclays PLC now owns 154,384 shares of the company's stock valued at $1,937,000 after buying an additional 127,595 shares during the last quarter. State Street Corp boosted its stake in Zymeworks by 6.1% in the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company's stock worth $14,706,000 after purchasing an additional 67,401 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Zymeworks by 93.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after purchasing an additional 311,107 shares during the last quarter. FMR LLC increased its stake in Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after purchasing an additional 1,525 shares in the last quarter. Finally, Stifel Financial Corp lifted its stake in shares of Zymeworks by 2.1% during the third quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock worth $924,000 after buying an additional 1,540 shares during the period. Institutional investors and hedge funds own 92.89% of the company's stock.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
